You are here

BMN 673

Why BioMarin hawked a phase III cancer drug to Medivation for $570M

BioPharma Dive

Wed, 08/26/15 - 08:47 am

Five Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Yahoo/Globe Newswire

Sun, 10/20/13 - 02:29 pm

BioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013

Yahoo/GlobeNewsWire

Sun, 09/29/13 - 01:33 pm

BioMarin Announces Oral Presentation of BMN 673 Most Recent Data on Breast and Ovarian Cancers at the European Cancer Congress 2013

Yahoo/GlobeNewsWire

Sat, 08/17/13 - 10:42 am

BioMarin Provides BMN 673 Program Update

Virtual Strategy

Sat, 07/27/13 - 11:25 am